Nexalin Technology Inc. (NASDAQ:NXL) on Wednesday reported clinical trial results in Brazil. The trial showed improvements in anxiety, depression, insomnia, and quality-of-life measures, supporting its drug-free neurostimulation approach.

Anxiety Response Reached 77.8%

Nexalin said an 8-week clinical trial in Brazil showed a 77.8% anxiety response rate. The rate applied to adults with generalized anxiety disorder and comorbid insomnia at the end of treatment.

The Institute of Psychiatry, Hospital das Clínicas, University of São Paulo, conducted the single-center, prospective, open-label trial using Nexalin's DIFS 15 mA, 77.5 Hz neurostimulation platform.

Participants received 20 sessions of transcranial alternating current stimulation over four weeks, followed by a four-week follow-up period.

Depression And Sleep Scores Improved

The company said anxiety scores fell by 14.73 points by Session 5. Anxiety scores fell by 18.30 points by Session 20, with reductions maintained at the 8-week follow-up.

Depression scores fell by 9.90 points by Session 20, while response and remission rates reached 66.7%.

Nexalin also reported sustained improvements in insomnia and quality of life. The trial reported no serious adverse events, seizures or manic/hypomanic switches.

From a treatment perspective, the company positioned the results as support for its platform. The platform is non-invasive, outpatient-friendly, and drug-free.

The company said it addresses delayed benefits, incomplete response, side effects, adherence challenges, and limited durability.

Neurostimulation Platform Supports Brazil Strategy

The company said the trial supports its clinical and sales strategy in Brazil, where it is preparing a product launch and sales campaign.

Regulators in China, Brazil, Oman, and Israel have approved Nexalin's Gen-2 15 milliamp neurostimulation device.

"This is another major clinical milestone for Nexalin and another powerful validation point for our proprietary non-invasive treatment platform," commented CEO Mark White.

Dr. David Owens, Nexalin's chief medical officer, said, "these findings are highly encouraging because they show improvement across multiple clinically relevant outcomes, not just a single endpoint."

"While these results should be interpreted in the context of an open-label pilot study, they provide a strong rationale for validation of all current published studies demonstrating Nexalin's strong clinical utility," added Owens.

U.S. Patent Protects Dynamic Frequency Stimulation Through 2042

Recently, Nexalin announced that the USPTO issued U.S. Patent No. 12,629,519 for its transcranial alternating-current dynamic frequency stimulation method.

The patent covers methods for anxiety, depression, and insomnia, conditions central to Nexalin's HALO™ Clarity and NeuroCare™ strategies.

The company expects the patent to provide U.S. intellectual property protection through 2042, strengthening its proprietary position in non-invasive, frequency-based deep-brain neurostimulation.

NXL Price Action: Nexalin Technology shares were up 6.67% at $0.48 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo via Shutterstock